Counselor Brook McKenzie and psychiatrist Dr Lauren Grawert argue cutting cravings isn't the same as recovery, which still takes commitment and therapy.
Recap by typeshit. Full story at Mad In America.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
A short reply clip on vision concerns tied to GLP-1 medications, a question that has followed reports of NAION eye stroke risk.
A TriNetX analysis of type 2 diabetes patients saw no excess breathing complications, though a hypocalcemia signal versus SGLT2 drugs needs a closer look.
Loading…